Scripps Cancer Center's 40th Annual Conference: Clinical Hematology & Oncology 2020


 

Immunotherapy for Advanced Stage TNBC: Modest Response with Monotherapy, Atezolizumab + Nab-Paclitaxel for PD-L1+ Disease, & Pembrolizumab May Gain FDA Approval

440 views
February 27, 2020
0 Comments
Login to view comments. Click here to Login
Breast Cancer Updates